|  |  |
| --- | --- |
| **PERSONAL INFORMATION** | Roberta Rostagno |
|  |
|   |  Via Arquà 10, 20131, Milan, Italy |
|  +39 3395960704  |
|  roberta.rostagno@unimib.it  |
|  |
| *Female* | *Date of birth* 02/01/1973 | Italian |

[Select you current working level]

|  |  |  |
| --- | --- | --- |
| **Enterprise** | **University** | **EPR** |
| [ ]  Management Level | [ ]  Full professor | [ ]  Research Director and 1st level Technologist / First Researcher and 2nd level Technologist |
| [ ]  Mid-Management Level | [ ]  Associate Professor | [ ]  Level III Researcher and Technologist |
| [ ]  Employee / worker level | [x]  Researcher and Technologist of IV, V, VI and VII level / Technical collaborator | [ ]  Researcher and Technologist of IV, V, VI and VII level / Technical collaborator |

|  |  |
| --- | --- |
| **WORK EXPERIENCE** |   |

[Add separate entries for each experience. Start from the most recent.]

|  |  |
| --- | --- |
| 03/02/2014 – | **Administrative Officer** |
| Università degli Studi di Milano Bicocca |
| * Support to research units belonging to University's science areas regarding reporting guidelines and procedures, projects' eligible costs, etc. Administration and management of national and international grants. Money transfer to projects' partner. Administrative and financial support to national and international partner. Management of institutional and commercial research project, invoicing.
 |
| B Business or sector Administration and management, research, financial  |
| 01/06/2013 – 02/02/2014 | **Administrative Officer** |
| Università degli Studi di Milano Bicocca |
| * Administrative activities at School of Medicine.
 |
| Business or sector Administration and management, |
| 01/02/2012 –31/05/2013 | **Grant manager of research unit** |
| Università degli Studi di Milano Bicocca |
| * Request, administration and management of national and international grants. Connection between national and international Partners and my supervisor. Administration and managements of research unit. Scientific secretary. Editing of Scientific publications. Secretary of the School of Specialization in medical oncology of the San Gerardo Hospital in Monza.
* Business or sector Administration and management
 |
| 01/05/2005 –31/01/2012  | **Research Scientist** |
| Università degli Studi di Milano Bicocca |
| * Anticancer research, molecular modeling study on anticancer active molecules. Validation of protein models finalized to look for drugs with antitumoral activity and design of new Tyrosine Kinase inhibitors.I was responsible for the molecular modeling research field. My main project was focused on the research of lead compounds that inhibit proteins activity and could be developed as drugs. I also studied the behaviour of protein-ligand interactions aver time by molecular dynamics simulations
* Business or sector Research
 |
| 01/01/2004 –30/04/2005  | **Visiting Scientist** |
| ETH Zurich, University of. Genève |
| * Funded by AIRC, Training on Molecular Modeling
* Business or sector Research
 |
| 01/04/1999 – 31/12/2003 | **Grant manager of research unit** |
| National Cancer Institute |
| * Request, administration and management of national and international grants. Connection between national and international Partners and my supervisor. Administration and managements of research unit. Scientific secretary. Editing of Scientific publications. Secretary of the School of Specialization in medical oncology of the San Gerardo Hospital in Monza.
* Business or sector Administration and management, Health care
 |
| 1998 – 31/03/1999 | **Researcher** |
| Istituto di ricerca chimica Ronzoni |
| * Biochemical research
* Business or sector Research
 |

|  |  |
| --- | --- |
| **EDUCATION AND TRAINING** |   |

|  |  |  |
| --- | --- | --- |
| 01/2018 – 06/2019 | **Master II Livello in Management of Research, Technology and Innovation** |  |
| MIP – Politecnico di Milano |
| * Project management, design thinking, public speaking,
 |
| 1991 - 1998 | **Master’s Degree in Chemistry** |  |
| Università degli Studi di Milano |
| * Chemistry, biochemistry, Physic, Mathematic
* Final grade 110/110
 |

|  |  |
| --- | --- |
| **PERSONAL SKILLS** |   |

|  |  |
| --- | --- |
| Mother tongue(s) | Italian |
|  |  |
| Other language(s) | **English**Listening B2Oral production B2Reading C1Writing skills B1 |
| **French**Listening A1Oral production A1Reading A1Writing skills A1 |

|  |  |
| --- | --- |
| Job-related skills | Experience in the organization/coordination of small teams.Experience in the preparation and management of research project (national and European)  |

|  |  |
| --- | --- |
| Digital skills | Windows 8, Windows 7, Windows Vista, Windows XPMicrosoft WordMicrosoft PowerPointMicrosoft ExcelSufin, Surplus, IRIS, Archiflow, U-Gov |

|  |  |
| --- | --- |
| Other skills | * Able to work in team
* Able to work under pressure
 |

|  |  |
| --- | --- |
| **ADDITIONAL INFORMATION** |   |

|  |  |
| --- | --- |
| Publications | C Gambacorti-Passerini, R Gunby, R. Piazza, A Galietta, **R Rostagno**, L Scapozza. Molecular mechanisms of resistance to imatinib in Ph-positive leukemias. Lancet Oncology, 4, 75,85, 2003.[Mologni L, Sala E, Cazzaniga S, **Rostagno R**, Kuoni T, Puttini M, Bain J, Cleris L, Redaelli S, Riva B, Formelli F, Scapozza L, Gambacorti-Passerini C.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17032739&query_hl=1&itool=pubmed_docsum). Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol. 2006 Oct;37(2):199-212.Redaelli S, Piazza R, **Rostagno R**, Magistroni V, Perini P, Marega M, Boschelli F, Gambacorti-Passerini C. Activity of bosutinib, dasatinib and nilotinib against 18 imatinib resistant BCR/ABL mutants. J Clinical Oncology. 2009 Jan; 27(3):469-71Luca Mologni, **Roberta Rostagno**, Stefania Brussolo, Phillip P. Knowles, Svend Kjaer, Judith Murray-Rust, Enrico Rosso, Alfonso Zambon, Leonardo Scapozza, Neil Q. McDonald, Vittorio Lucchini, Carlo Gambacorti-Passerini. Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96Spinelli, R., Piazza, R., Pirola, A., Valletta, S., **Rostagno, R**., Mogavero, A., et al. (2012). A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data. In Computational Intelligence Methods for Bioinformatic and Biostatistics (pp. 73-82). Springer-Verlag Berlin HeidelbergRedaelli S, Mologni L, **Rostagno R**, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C. [Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.](http://www.ncbi.nlm.nih.gov/pubmed/23044928) Am J Hematol. 2012 Nov;87(11):E125-8 |